BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23990312)

  • 1. The importance of villous physiology and morphology in mechanistic physiologically-based pharmacokinetic models.
    Chen EP; Tai G; Ellens H
    Pharm Res; 2014 Feb; 31(2):305-21. PubMed ID: 23990312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.
    Gertz M; Harrison A; Houston JB; Galetin A
    Drug Metab Dispos; 2010 Jul; 38(7):1147-58. PubMed ID: 20368326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
    Chen KF; Chan LN; Lin YS
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):493-512. PubMed ID: 32710209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Pooled Cryopreserved Human Enterocytes as an In vitro Model for Assessing Intestinal Clearance and Drug-Drug Interactions.
    Wong S; Doshi U; Vuong P; Liu N; Tay S; Le H; Kosaka M; Kenny JR; Li AP; Yan Z
    Drug Metab Lett; 2018; 12(1):3-13. PubMed ID: 29237391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
    Quinney SK; Zhang X; Lucksiri A; Gorski JC; Li L; Hall SD
    Drug Metab Dispos; 2010 Feb; 38(2):241-8. PubMed ID: 19884323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach.
    Brussee JM; Yu H; Krekels EHJ; Palić S; Brill MJE; Barrett JS; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
    Pharm Res; 2018 Jul; 35(9):182. PubMed ID: 30062590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption.
    Badhan R; Penny J; Galetin A; Houston JB
    J Pharm Sci; 2009 Jun; 98(6):2180-97. PubMed ID: 18855913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall.
    Darwich AS; Burt HJ; Rostami-Hodjegan A
    Eur J Pharm Sci; 2019 Apr; 131():195-207. PubMed ID: 30776469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction.
    Gertz M; Houston JB; Galetin A
    Drug Metab Dispos; 2011 Sep; 39(9):1633-42. PubMed ID: 21632965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
    Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
    J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Cryopreserved Human Intestinal Mucosa and Cryopreserved Human Enterocytes in the Evaluation of Herb-Drug Interactions: Evaluation of CYP3A Inhibitory Potential of Grapefruit Juice and Commercial Formulations of Twenty-Nine Herbal Supplements.
    Loretz C; Ho MD; Alam N; Mitchell W; Li AP
    Drug Metab Dispos; 2020 Oct; 48(10):1084-1091. PubMed ID: 32719085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A New Intestinal Model for Analysis of Drug Absorption and Interactions Considering Physiological Translocation of Contents.
    Asano S; Yoshitomo A; Hozuki S; Sato H; Kazuki Y; Hisaka A
    Drug Metab Dispos; 2021 Jul; 49(7):581-591. PubMed ID: 33962977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus.
    Heikkinen AT; Baneyx G; Caruso A; Parrott N
    Eur J Pharm Sci; 2012 Sep; 47(2):375-86. PubMed ID: 22759901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
    Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
    Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new physiologically based pharmacokinetic model for the prediction of gastrointestinal drug absorption: translocation model.
    Ando H; Hisaka A; Suzuki H
    Drug Metab Dispos; 2015 Apr; 43(4):590-602. PubMed ID: 25616403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.